AYTU BIOPHARMA, INC. - Form 8-K Summary
Business Context and Reporting Period
Company: Aytu BioScience, Inc. (trading as AYTU BIOPHARMA, INC.)
Filing Date: November 4, 2019 (Reporting events as of October 31, 2019 and November 1, 2019)
Event: Completion of an asset acquisition from Cerecor Inc. and entry into related definitive agreements.
The Company closed the acquisition of certain assets and liabilities from Cerecor Inc. on November 1, 2019. The assets were transferred to a newly formed subsidiary, Aytu Therapeutics, LLC. This filing details amendments to the purchase agreement, the issuance of preferred stock as consideration, and various voting and financial obligations associated with the transaction.
Key Financial Metrics and Transaction Details
This filing is a Current Report (8-K) and does not contain standard periodic financial statements (revenue, profit, cash flow, or margins). Key financial data points related to the transaction include:
- Consideration Issued: 9,805,845 shares of Series G Convertible Preferred Stock issued to Cerecor Inc.
- Valuation of Consideration: $12.5 million aggregate value.
- Price Per Share: $1.2747 per share of Series G Preferred Stock.
- Assumed Liability: The Company assumed a fixed payment obligation to Deerfield CSF, LLC of approximately $16.575 million.
- Escrow Deposit: Armistice Capital Master Fund, Ltd. deposited $15,262,500 into an escrow account to secure the assumed obligation.
Material Changes and Agreements
The following material agreements and changes were executed in connection with the acquisition:
- Amendment to Asset Purchase Agreement: Executed on November 1, 2019, modifying definitions, indemnification obligations, and schedules of the original October 10, 2019 agreement.
- Deerfield Obligation Assignment: The Company assumed the $16.575 million obligation. This required a Consent and Limited Waiver Agreement involving Deerfield, Avadel, and Armistice Capital. Armistice and Cerecor provided guarantees for this obligation.
- Voting Agreements:
- Seller (Cerecor): Agreed to vote for 12 months in favor of a proposed merger with Innovus Pharmaceuticals, Inc. and against impediments to that merger.
- Securityholders and Officers: Agreed to vote for 12 months in favor of converting the Series G Preferred Stock to common stock and in favor of the Innovus merger.
- Registration Rights: Cerecor received registration rights for shares of common stock issuable upon conversion of the Series G Preferred Stock.
- Transition Services: A Transition Services Agreement was entered into for transitional support between the Company and Cerecor.
Guidance, Outlook, and Risks
Outlook and Management Commentary: The filing indicates the Company is pursuing a merger with Innovus Pharmaceuticals, Inc., as evidenced by the voting agreements requiring support for this transaction. The Series G Preferred Stock is designed to convert to common stock upon stockholder approval, subject to a lock-up agreement until July 1, 2020.
Risks and Contingencies:
- Stockholder Approval: The conversion of Series G Preferred Stock is contingent upon stockholder approval meeting Nasdaq rules.
- Merger Dependency: Several voting agreements and the strategic direction are tied to the approval of the merger with Innovus Pharmaceuticals. If the merger is terminated, certain voting agreements automatically terminate.
- Financial Obligation: The Company has assumed a significant fixed payment obligation ($16.575 million) which is secured by guarantees and an escrow account.
- Financial Statements: Financial statements for the acquired business are not included in this filing and are due within 71 calendar days.
Investor Verification Checklist
- Verify the status of the proposed merger with Innovus Pharmaceuticals, Inc., as the voting agreements and preferred stock conversion are contingent upon it.
- Review the full text of the "Consent and Limited Waiver Agreement" (Exhibit 10.6) to understand the terms of the $16.575 million Deerfield Obligation and the guarantees provided by Armistice and Cerecor.
- Monitor the upcoming filing of the acquired business's financial statements, which are required within 71 days of this report.
- Confirm the timeline for stockholder approval required to convert the Series G Preferred Stock into common stock.
- Check for any updates regarding the lock-up agreement on the underlying common stock, which extends until July 1, 2020.